Enovis Posts Mixed 2025 Results Amid Goodwill Impairment
Event summary
- Enovis reported full-year 2025 sales growth of 7% on a reported basis and 6% organically, with Reconstructive sales up 10% and Prevention & Recovery sales up 4%.
- Fourth-quarter 2025 net sales grew 3% on a reported basis and 2% organically, with Reconstructive sales up 7% and Prevention & Recovery sales down 1%.
- Enovis reported a full-year net loss of $1.18 billion, including a $1.05 billion goodwill impairment charge.
- 2026 revenue guidance is $2.31-2.37 billion, with adjusted EBITDA expected to be $425-435 million.
The big picture
Enovis's 2025 results highlight continued commercial momentum in its Reconstructive segment, but the significant goodwill impairment charge underscores the challenges of integrating acquisitions and navigating volatile market conditions. The company's focus on operational efficiency and disciplined financial management will be critical as it positions itself for durable growth in a competitive medical technology landscape.
What we're watching
- Integration Progress
- How Enovis will advance its second-year Lima integration priorities and sustain operational improvements.
- Market Conditions
- Whether Enovis can maintain commercial execution and financial discipline amid evolving macroeconomic conditions.
- Growth Strategy
- The pace at which Enovis can drive capital-efficient growth while improving operational efficiency.
Related topics